TGF-β3 containing mouthwash intended to reduce the severity of oral mucositis in cancer patients receiving chemotherapy reached phase II clinical trials but failed to demonstrate an advantage compared with placebo [139,140]. The gene discussed is TGFB3; the disease is oral mucositis.